EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Graft-derived VWF drives platelet activation and thrombocytopenia during porcine liver xenotransplantation to brain-dead human recipients

Liang Zhao, Sokratis A Apostolidis, Aae Suzuki, Amrita Sarkar, Qian Guo, Felix Li, Alex Sagar, John Fallon, Mohamed A Elzawahry, Syed Hussain Abbas, Leanne Lanieri, Kristen Getchell und 8 weitere

Journal of Clinical Investigation · 01.05.2026 · 136 (9)

DOI: 10.1172/jci200800 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 10.03.2026. Verfasst von Liang Zhao und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Thrombocytopenia, Liver Transplantation, Platelet Activation, Transplantation, Heterologous. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Genetically engineered porcine livers are being developed as a bridge therapy for acute liver failure, providing detoxification and restoration of hepatic protein synthesis. Severe xenograft-associated thrombocytopenia remains a major limitation, and human mechanistic data are scarce. METHODS Platelet kinetics were characterized in 3 human decedents undergoing extracorporeal cross-circulation with transgenic porcine livers. Platelet counts, transfusion requirements, and clearance patterns were assessed to distinguish consumption from marrow suppression or hypersplenism. Antibody- and complement-directed inhibitors were administered to test immune-mediated mechanisms. Mechanistic studies focused on porcine von Willebrand factor–dependent (pVWF-dependent) platelet activation, including ex vivo blockade with the anti-VWF nanobody caplacizumab, a VWF-directed antibody fragment that prevents VWF-platelet binding. A fourth decedent received caplacizumab during porcine liver perfusion. RESULTS In all 3 initial cases, 80%–90% of circulating and transfused platelets were rapidly cleared, a pattern inconsistent with marrow suppression or hypersplenism. Antibody and complement inhibition failed to ameliorate thrombocytopenia. Recipient plasma induced robust pVWF-mediated platelet activation analogous to human type IIb von Willebrand disease, which was completely abrogated ex vivo by caplacizumab. In a fourth decedent treated with caplacizumab, aberrant platelet activation was prevented, although full hematologic recovery was limited by preexisting disseminated intravascular coagulation. CONCLUSIONS Early thrombocytopenia during porcine liver xenotransplantation appears to be primarily driven by pVWF-mediated platelet activation rather than by classical immune or splenic mechanisms. Targeted VWF blockade with agents such as caplacizumab may mitigate platelet loss and improve the safety profile of extracorporeal porcine liver support in acute liver failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombocytopeniaLiver TransplantationPlatelet ActivationTransplantation, Heterologousvon Willebrand FactorAnimalsHumansSwineFemaleMaleHeterograftsAnimals, Genetically ModifiedMiddle AgedBlood Platelets

Stichwörter der Autor:innen

HematologyTransplantationVascular biology

Substanzen

von Willebrand Factor

Autor:innen und Institutionen

  • Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Transplantation, Department of Surgery, New York University Langone Health, New York, New York, USA.
  • Nuffield Department of Surgical Sciences, University of Oxford, The Churchill Hospital, Oxford, United Kingdom.
  • eGenesis, Cambridge, Massachusetts, USA.
  • Penn Transplant Institute, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NIAMS NIH HHS
  • NIH
  • HTRS

Zitieren

APA

Zhao, L., Apostolidis, S. A., Suzuki, A., Sarkar, A., Guo, Q., Li, F., Sagar, A., Fallon, J., Elzawahry, M. A., Abbas, S. H., Lanieri, L., Getchell, K., Low, S. C., Olthoff, K. M., Furth, E. E., Keating, B. J., Friend, P., Poncz, M., Shaked, A., & Abrams, C. S. (2026). Graft-derived VWF drives platelet activation and thrombocytopenia during porcine liver xenotransplantation to brain-dead human recipients. Journal of Clinical Investigation, 136(9). https://doi.org/10.1172/jci200800

Vancouver

Zhao L, Apostolidis SA, Suzuki A, Sarkar A, Guo Q, Li F, et al. Graft-derived VWF drives platelet activation and thrombocytopenia during porcine liver xenotransplantation to brain-dead human recipients. Journal of Clinical Investigation. 2026;136(9). doi:10.1172/jci200800

BibTeX
@article{Zhao2026,
  author = {Zhao, Liang and Apostolidis, Sokratis A and Suzuki, Aae and Sarkar, Amrita and Guo, Qian and Li, Felix and Sagar, Alex and Fallon, John and Elzawahry, Mohamed A and Abbas, Syed Hussain and Lanieri, Leanne and Getchell, Kristen and Low, Susan C and Olthoff, Kim M and Furth, Emma E and Keating, Brendan J and Friend, Peter and Poncz, Mortimer and Shaked, Abraham and Abrams, Charles S},
  title = {Graft-derived VWF drives platelet activation and thrombocytopenia during porcine liver xenotransplantation to brain-dead human recipients},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {9},
  doi = {10.1172/jci200800}
}
Kostenlos starten →